FDA Grants Orphan Drug Status to (Z)-Endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics receives FDA orphan drug designation for (Z)-endoxifen to treat Duchenne muscular dystrophy, a rare genetic muscle-wasting disease.